GSK: GLAXOSMITHKLINE PLC Profile

Ticker

Advertisement

Choose a Broker

Dynamic view of the market

U.S. Markets open in 64 hrs, 25 mins

Symbol	Value	Change	Percentage Change
DJIA	11,288.54	73.03	0.65%
NASDAQ	2,245.38	-6.08	-0.27%
S&P 500	1,262.90	1.38	0.11%

GLAXOSMITHKLINE PLC

GSK

Stock price

46.77 1.59 3.52%

as of 01:00 PM EDT on 07/03/2008 in USD (NYSE Delay: 20 mins.)
Extended Hours

— — —

Analyst Consensus

Hold
Analyst Consensus

Strong Buy

Buy

Hold

Sell

Strong Sell
- Add to Portfolio
- Add to Alerts
Discuss: GSK

Insightful information about industries, companies, and the people who lead them.

Learn More.

2007 Sales	2007 Sales Growth	2007 Net Income	2006 Employees
$45,816,100,000	0.7%	$10,605,700,000	100,000

Key Executives: GSK

Name	Title	Officer Since
Andrew Witty	CEO	1/31/08
Julian Heslop	CFO	4/1/05
Bill Louv	Chief Information Officer	-
Lawrence Culp	Director	7/1/03
Moncef Slaoui	Chairman of the Board, Divisional/Director	5/17/06
Sir Christopher Gent	Chairman of the Board/Director	6/1/04
Dr. Stephanie Burns, Ph.D.	Director	2/12/07
Dr. Daniel Podolsky	Director	7/1/06

View All Key Executives

Andrew Witty, Appointed on 31st January 2008. CEO Designate. He will succeed Dr Garnier on 21st May 2008. Mr Witty joined the Group in 1985 and has held senior positions in Asia, Africa, Europe and the USA. In January 2003 he was appointed President, Pharmaceuticals Europe. He has served as a board member of the Singapore Economic Development Board. He is a member of the INSEAD UK Council, a Director of the Office for Strategic Coordination of... View Full Profile

Andrew Witty

Lawrence Culp, Appointed on 1st July 2003. Non-Executive Director. Mr Culp is President and Chief Executive Officer of Danaher Corporation. Prior to joining Danaher, he held positions in Accenture, previously Andersen Consulting.... View Full Profile

Lawrence Culp

Julian Heslop, Appointed on 1st April 2005. Chief Financial Officer. Mr Heslop joined Glaxo Wellcome as Financial Controller in April 1998. In January 2001 he was appointed Senior Vice President, Operations Controller. Prior to joining the Group he held senior finance roles at Grand Metropolitan.... View Full Profile

Julian Heslop

Dr. Moncef Slaoui, Appointed on 17th May 2006. Chairman, Research & Development. Dr Slaoui joined GSK Biologicals in 1988 where he engineered the development of a robust vaccines pipeline. He has a PhD in Molecular Biology and Immunology from Universite Libre de Bruxelles.... View Full Profile

Moncef Slaoui

Sir Christopher Gent , Appointed on 1st June 2004. Chairman. Sir Christopher was the Chief Executive Officer of Vodafone Group plc, until his retirement in July 2003. He is a Non-Executive Director of Lehman Brothers Holdings Inc., a Non-Executive Director of Ferrari S.p.A., a member of KPMG's Chairman's Advisory Group, a Senior Adviser at Bain & Co. and a member of the Advisory Board of Reform.... View Full Profile

Sir Christopher Gent

Dr. Stephanie Burns, Appointed on 12th February 2007. Non-Executive Director. Dr Burns is Chairman, President and Chief Executive Officer of Dow Corning Corporation. She is also a member of the American Chemical Society and sits on the Executive Committee of the Society of Chemical Industry, America Section, serves on the Board of Directors of the American Chemistry Council, and on the Board of Directors for the Society for Women's Health... View Full Profile

Dr. Stephanie Burns, Ph.D.

Dr. Daniel Podolsky, Appointed on 1st July 2006. Non-Executive Director. Dr Podolsky is Mallinckrodt Professor of Medicine and Chief of Gastroenterology at Massachusetts General Hospital and Harvard Medical School as well as Chief Academic Officer of Partners HealthCare System. He is also Chairman of the Board and Scientific Co-Founder of the GI Company.... View Full Profile

Dr. Daniel Podolsky

Mr Louv succeeded Dr Calhoun as Chief Information Officer in January 2007. He is responsible for information technology, a global function that enables key business processes across all parts of the Group. He joined the Group in 1994 and has held a number of increasingly senior roles in IT, including for US Pharmaceuticals and GSK's R&D functions.... View Full Profile

Bill Louv

Sir Deryck Maughan, Appointed on 1st June 2004. Non-Executive Director. Sir Deryck is a Managing Director of Kohlberg Kravis Roberts & Co. He was formerly Chairman and CEO of Citigroup International and of Salomon Brothers Inc. He is a Non-Executive Director of Reuters Group plc and BlackRock Inc.... View Full Profile

Sir Deryck Maughan

Dr. Ronaldo Schmitz, Appointed on 23rd May 2000. Non-Executive Director. Dr Schmitz was formerly a Non-Executive Director of Glaxo Wellcome plc. He is a Non-Executive Director of Legal & General Group plc, a member of the Board of Directors of Rohm and Haas Company and Cabot Corporation and of the Supervisory Board of SICK AG.... View Full Profile

Dr. Ronaldo Schmitz

Dr. Ronaldo Schmitz, Appointed on 23rd May 2000. Non-Executive Director. Dr Schmitz was formerly a Non-Executive Director of Glaxo Wellcome plc. He is a Non-Executive Director of Legal & General Group plc, a member of the Board of Directors of Rohm and Haas Company and Cabot Corporation and of the Supervisory Board of SICK AG.... View Full Profile

Jean-Pierre Garnier

Sir Ian Prosser, Appointed on 23rd May 2000. Senior Independent Director. Sir Ian was formerly a Non-Executive Director of SmithKline Beecham plc. He is Non-Executive Deputy Chairman of BP plc, a Non-Executive Director of Sara Lee Corporation and a member of the CBI President's Committee.... View Full Profile

Sir Ian Prosser

Sir Crispin Davis, Appointed on 1st July 2003. Non-Executive Director. Sir Crispin is Chief Executive of Reed Elsevier PLC. Prior to that, he was Chief Executive of Aegis Group plc, which he joined from Guinness plc, where he was a member of the main board and Group Managing Director of United Distillers. He spent his early career with Procter & Gamble.... View Full Profile

Sir Crispin Davis

Sir Robert Wilson, Appointed on 1st November 2003. Non-Executive Director. Sir Robert is Non-Executive Chairman of BG Group plc and The Economist Group and was previously Executive Chairman of Rio Tinto.... View Full Profile

Sir Robert Wilson

Tom de Swaan, Appointed on 1st January 2006. Non-Executive Director. Mr de Swaan was a member of the Managing Board and Chief Financial Officer of ABN AMRO until January 2006. He is a member of the Board of Directors of Zurich Financial Services and Vice Chairman of the Supervisory Board and Chairman of the Audit Committee of Royal Ahold, a member of the Supervisory Boards of Royal DSM and of Corporate Express, and Vice Chairman of the... View Full Profile

Tom de Swaan

Christopher Viehbacher, Appointed on 31st January 2008. President, US Pharmaceuticals. Mr Viehbacher joined the Group in 1988 and has held a variety of senior positions in Europe and Canada. He was appointed President, US Pharmaceuticals in January 2003. He served on the European Commission approved G10 working group to restore the competitiveness of the EU Pharmaceutical industry. He is a board member of PhRMA, the CEO Roundtable on Cancer and... View Full Profile

Christopher Viehbacher

Professor Sir Roy Anderson, Appointed on 1st October 2007. Non-Executive Director. Professor Anderson is the Professor of Infectious Disease Epidemiology in the Faculty of Medicine, Imperial College, London and until September 2007, was the Chief Scientific Adviser at the Ministry of Defence in the UK. He will become Rector of Imperial College in July 2008.... View Full Profile

Professor Sir Roy Anderson

Mr Gray became responsible for the Group's operations in Europe in January 2008. He joined Beecham in 1988 and, prior to his current appointment, was Senior Vice President and General Manager, Pharmaceuticals UK.... View Full Profile

Eddie Gray

Mr Dunoyer was appointed President, Pharmaceuticals Japan in March 2003. He joined the Group in 1999 and was Senior Vice President and Regional Director, Japan until his current appointment.... View Full Profile

Marc Dunoyer

Dr Greig leads the pharmaceutical operations outside the USA, Japan and most of Europe, covering more than 100 countries. He joined the Group in 1980 and was Senior Vice President, Worldwide Business Development for R&D prior to his current appointment in March 2003.... View Full Profile

Dr. Russell Greig

Dr Pulman is responsible for the Global Manufacturing and Supply organisation and Global Procurement. He trained as a microbiologist and joined Glaxo in 1978. He has broad experience of manufacturing operations having previously led the Primary Supply, European manufacturing, North American manufacturing, Global Logistics and Manufacturing Strategy organisations.... View Full Profile

Dr. David Pulman

Mr Clarke is responsible for the Consumer Healthcare business which produces oral, over-the-counter and nutritional healthcare products. He joined Beecham in 1976 and was the President of the Futures Group before his current appointment in January 2006.... View Full Profile

John Clarke

Mr Learmouth is responsible for the Group's investor relations, internal and external communications, its image and partnerships with global communities. He joined Glaxo in 1991 and was Vice President, Global Investor Relations, before appointment to his current position in July 2006.... View Full Profile

Duncan Learmouth

Simon Bicknell appointed secretary in May 2000. He is a barrister and joined the Group in 1984. He is secretary to all the Board Committees.... View Full Profile

Simon Bicknell

Mr Phelan is responsible for benefits, compensation, recruitment, organisation development, leadership development and succession planning, human resource information systems and employee health management. He was a lawyer in private practice before joining Smith Kline & French in 1981.... View Full Profile

Dan Phelan

Top Competitors: GSK

View Detailed Competitors Chart

Insider Trends: GSK
Sentiment for GSK is —
- 0M
- 2M
- 4M
- 6M
- Market Value of Insider Sales
- Market Value of Insider Purchases
Total dollar value of all insider purchases and sales over 12 months
View All Insider Sentiment

Insider Transactions: GSK

Date	Name	Shares	Transaction Type	Market Value
12/14/07	STOUT DAVID M	3,761	Planned Sale	$200,000.00
12/06/07	STOUT DAVID M	294,416	Planned Sale	$15.50 M
12/05/07	GREIG RUSSELL	12,500	Planned Sale	$658,713.00

View All Insider Activity

Ownership Breakdown : GSK

Large Block Holder Type	Number
Institutions	596.00
Mutual Fund	292.00
Other Major	3.00

Full Details

Indices : GSK

Symbol	Name	Last Trade	Change

View all Indices that include GSK

Short Interest Volume: GSK

Data as of —

Current Short Interest Shares	1.10 B
Current Short Interest Ratio	7.20
Float	—

Short Interest as % of Float	—
Average Daily Volume	1.51 M
Outstanding Shares	2.64 B

Full Details

SEC Filings: GSK

Accepted Date	Description
07/03/2008	SEC Filing: Foreign Issuer Report
07/02/2008	SEC Filing: Foreign Issuer Report
07/01/2008	SEC Filing: Foreign Issuer Report

View all SEC Filings

Get Profile Details for:

- Help & Feedback

Market Movers

Related Resources

My Portfolios

AOL Real-Time Streaming Quotes

GLAXOSMITHKLINE PLC

GSK

Stock price

46.77 1.59 3.52%

as of 01:00 PM EDT on 07/03/2008 in USD (NYSE Delay: 20 mins.)
Analyst Consensus
- Strong Buy
- Buy
- Hold
- Sell

Live Updates:

Ticker

Dynamic view of the market

GLAXOSMITHKLINE PLC

GSK

Stock price

Extended Hours

Analyst Consensus

GLAXOSMITHKLINE PLC Profile

Key Executives: GSK

Top Competitors: GSK

Insider Trends: GSK

Insider Transactions: GSK

Ownership Breakdown : GSK

Indices : GSK

Short Interest Volume: GSK

SEC Filings: GSK

Quote Details

Classic Chart

Advanced Chart BETA

Real-Time Headlines

Message Boards

Profile

Earnings Analysis

Event Calendar

Financials

Market Movers

Related Resources

GLAXOSMITHKLINE PLC

GSK

Stock price

Analyst Consensus